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The effect of popliteal sciatic nerve block with methylprednisolone in the management of
postinjection sciatic neuropathy after clinical and electrophysiological examination
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Background/aim: This study aimed to investigate the effects of popliteal sciatic nerve block (PSNB) in the treatment of postinjection
sciatic neuropathy (PISN) resistant to conservative treatments.
Materials and methods: Patients diagnosed with PISN were included in the study. A damaged branch of the sciatic nerve was detected
after neurological and electrophysiologic studies (EPSs). Visual analogue scale (VAS) was administered before, one hour after, and
one month after the procedure. Also Leeds Assessment of Neuropathic Symptoms and Signs pain scale (LANSS) was administered
before and one month after the procedure. The effects of EPSs findings and loss of muscle strength on the VAS and LANSS scores that
measured after PSNB were evaluated.
Results: PSNB was performed in 17 patients (12 males and 5 females) with a diagnosis of PISN. Their mean age was 54.95 ± 12.55 years,
and the mean duration of symptoms was 3.53 ± 1.28 months. The EPS findings revealed a lateral truncus injury in 5, a medial truncus
injury in 3, and injury to both in 9 patients. The initial muscle power scale scores were grade 0 in 2, grade 2 in 1, grade 3 in 7, grade 4 in
5, and grade 5 in 2 patients. The initial VAS and LANSS scores were 7.53 ± 1.06 and 17.35 ± 3.12. The mean VAS scores at the first hour
and one month after the procedure decreased to 2.53 ± 1.70 and 4.18 ± 1.74 while the mean LANSS score one month after the procedure
was reduced to 7.88 ± 5.84. The effects of EPSs findings and loss of muscle strength were found significant (p = 0.001), but the duration
of symptoms was not found significant (p = 0.36) on the VAS and LANSS scores that measured after PSNB.
Conclusion: The outcome of this research proved the effectiveness of PSNB with methylprednisolone in the management of PISN,
especially in patients whose pain was located below the knee. EPSs findings and loss of muscle strength indicated the severity of the
nerve damage affect the success of PSNB in pain management, but the length of time that elapsed after the nerve injury did not.
Key words: Sciatic neuropathy, postinjection neuropathy, popliteal block

1. Introduction
The most common injury mechanism that affects the
sciatic nerve is receiving an intramuscular injection in
the gluteal region, which is an iatrogenic cause with a
frequency of 28% [1]. Direct trauma from the needle
is often associated with the use of a more medial and/
or inferior site for the injection [2]. There is a consensus
the upper outer region of the buttock is the most reliable
location for an injection [3]. In addition, the patient’s
subcutaneous tissue and gluteus muscle thickness in this
area are effective at preventing sciatic nerve injury after
intramuscular injection [4]. The other mechanism for
postinjection sciatic neuropathy (PISN) is nerve fiber
damage induced by neurotoxic chemicals in the agent

injected. The most common intramuscularly delivered
agents that are injected into the nerve are analgesics,
antiemetics, antibiotics, vitamins, vaccines, and steroid
drugs [5].
The clinical presentation of a sciatic nerve injury
includes immediate electric-like shock sensations down
to the extremity. Concomitantly, patients often report the
onset of variable motor and sensory deficits with pain
from the injection site in the buttock that extends over the
knee and may even be felt in the foot [6].
Electrophysiologic studies (EPSs) are more sensitive
than a physical examination, which makes them invaluable
in helping to define the location and to grade the severity
of the lesion, exclude other lesions, and predict recovery
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[7]. EPSs are best performed three or more weeks after
the injury since Wallerian degeneration will have been
completed by this time.
Recommended treatments for PISN include surgical
and nonsurgical methods including the administration
of drugs and physical therapy. Physiotherapy is often
required, but patients have difficulty completing early
physiotherapy due to severe pain. Adequate pain
management may not be possible in some patients when
the time required for the drug to reach the effective dose
is long or when the dose cannot be increased due to side
effects. However, performing physiotherapy a long time
after the nerve damage occurs may lead to permanent
neurological deficits [8].
Successful reduction of pain in PISN increases
compliance with physiotherapy in patients so that impaired
motor and sensory functions can be restored. Therefore,
the purpose of this study was to present popliteal sciatic
nerve block (PSNB) therapy for pain management in PISN
that is resistant to conservative treatments.
2. Materials and methods
2.1 Participants
Twenty patients who complained of varying degrees of
pain, loss of sensation, and weakness in the lower extremity
following gluteal injection who visited the Algology Clinic
of Health Sciences University at the Yüksek İhtisas Research
and Training Hospital in Bursa between January and June
2019 were included in this study. The diagnosis of PISN
was based on the patient’s clinical history, neurological
examination, and EPSs findings.
The inclusion criteria were as follows: 1) pain that
extends from the knee to the foot, which is certain to
develop after gluteal injection, 2) pain that is resistant to
drug therapy and a VAS score > 3, 3) damage detection in
the medial or lateral truncus of the sciatic nerve on EPSs.
The exclusion criteria were as follows: 1) the presence of
lumbar radiculopathy and other causes of sciatica, 2) pain
that extended from the gluteal region, 3) successful pain
therapy with drugs and a VAS score ≤ 3; and 4) the use of
anticoagulants.
This prospective randomized controlled study received
approval by the Local Ethics Committee (Health Sciences
University of the Bursa Yüksek İhtisas Research and
Training Hospital Clinical Research Ethics Committee,
Decision Number 2011-KAEK-25 2018/09-7). After being
given information about the study, written informed
consent was obtained from all participants.
2.2. Study design
A neurophysiology specialist physician performed the
neurological examinations and EPSs in all patients and
made the diagnosis of PISN. EPSs were done between
three weeks and six months after the nerve injury. A pain

physician identified the patients suitable for PSNB and
performed the procedure using ultrasound guidance.
The patients were allowed to continue their drug therapy
at the same dose during the study. Demographic data,
duration of symptoms, causes of pain, pain localization,
neurological examination findings, and nerve damage
detected by the EPS were recorded. Visual analogue scale
(VAS) was administered before, one hour after, and one
month after the procedure. Also Leeds Assessment of
Neuropathic Symptoms and Signs pain scale (LANSS) was
administered before and one month after the procedure.
The study design is illustrated in Figure 1.
2.3. Intervention
Blocks were performed in an operating room by a
pain physician with a 12–18 MHz linear ultrasound
transducer (MyLab 30; Esaote SpA, Genoa, Italy) under
sterile conditions with the patient placed in a prone
position. Intravenous access, supplemental oxygen, and
standard monitoring (electrocardiogram, noninvasive
blood pressure monitoring, and pulse oximetry) were
established in all patients. None of the patients experienced
complications during or after the procedure.
The PSNB technique was as follows. A linear ultrasound
transducer was placed in the transverse position at the
popliteal crease, and then the popliteal artery and vein
were identified. The biceps femoris muscle was observed
lateral to the popliteal artery, and the semimembranosus
and semitendinosus muscles were identified in the medial
plane. The tibial nerve was seen as a hyperechoic, rounded
structure lateral to the popliteal vein. The common
peroneal nerve was visible lateral to the tibial nerve. The
transducer was advanced proximally until the tibial and
peroneal nerves that come together to form the sciatic nerve
were visualized before dividing. A 10-cm, 22-G Stimuplex
needle (B. Braun Medical Ltd., Melsungen, Germany) was
inserted from 2–3 cm lateral to the transducer using an inplane approach from a lateral to medial direct. The needle
tip was contacted with either branch of the nerve; during
nerve stimulation (0.5 mA for 0.1 ms), a motor response
of the calf or foot was observed. The needle tip was then
placed into the space between the two components of the
sciatic nerve that were slightly separated by adipose tissue.
It was observed that 80 mg methylprednisolone with
2% lidocaine in a 10-mL solution was distributed in the
epineural sheath, and the tibial and peroneal nerves were
separated.
The injection site was pressed to achieve hemostasis.
Sensory and motor examinations were performed to ensure
a successful block assessment. Sensory examinations of
the dorsum of the foot for the common peroneal nerve
and the middle part of the foot for the tibial nerve were
performed. The plantar dorsiflexion strength of the ankle
was evaluated during a motor examination.
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Diagnosed with PISN (n = 20)
neurological and electrophysiological
$O&)3*&(3+*
PSNB applied (n = 17)

Excluded (n = 3)
Pain that extends from the gluteal
region (n = 2)
Use of anticoagulants (n = 1)

Pain assessment (n = 17)
One hour and one month after the
PSNB by VAS and LANSS

Analysis (n = 17)

Figure 1: Design of the study. PISN, postinjection sciatic neuropathy; PSNB, popliteal
sciatic nerve block; VAS, Visual Analog Scale; LANSS, Leeds Assessment of Neuropathic
Symptoms and Signs.

2.4. Evaluation parameters
The severity of pain along the sciatic nerve distribution was
evaluated using the VAS, which was developed by Price et
al. [9]. Patients rated their pain on a scale of 0–10, with 0
representing no pain and 10 representing the worst pain
imaginable. The pain assessment was performed before,
one hour after, and one month after the PSNB by the VAS.
The amount of neuropathic pain was confirmed with
the Turkish version of the LANSS pain scale [10]. This scale
has a 24 total possible points; a LANSS score ≥12 indicates
that neuropathic pain mechanisms are effective, while a
LANSS score <12 signifies that current neuropathic pain
mechanisms are not effective.
2.5. Statistical analysis
In this study, the descriptive statistics were expressed
as follows: the mean ± standard deviation (SD) for
continuous variables with a normal distribution; the
median (interquartile range) for continuous variables
without a normal distribution; frequencies and percentages
for categorical variables. To determine the normality of
continuous variables, the results of the Shapiro–Wilk test
were evaluated. The change in VAS score over time was
evaluated using the Friedman test. The difference between
the initial and final LANSS score was examined with the
Wilcoxon test. The significance level was set as p < 0.05.
The data analysis was performed using the Statistical
Package for the Social Sciences (SPSS) software, version
23.0 (IBM Corporation, Armonk, NY, US).
3. Results
PSNB was performed in 17 patients diagnosed with PISN:
12 (70.6%) males and 5 (29.4%) females. Their mean age
was 54.95 ± 12.55 (range: 27–75) years, and the mean
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duration of symptoms was 3.53 ± 1.28 (2–6) months.
(Table 1)
The EPS findings revealed lateral truncus injury in
5 (29.4%), medial truncus injury in 3 (17.6%), and both
types of truncus injury in 9 (52.9%) patients. In 6 of these
9 (52.9%) patients, severe partial or full denervation in the
muscles innervated from the lateral trunk was found, and
mild partial denervation in the muscles innervated from
the medial trunk was observed. In 3 of these 9 (52.9%)
patients, severe partial denervation or full denervation
in the muscles innervated by both trunci were recorded.
Of the 5 patients with only a lateral trunk deficit, 2 had
mild partial denervation, while 3 exhibited complete
denervation of the muscles innervated by the lateral trunk.
In 3 patients with only a medial trunk deficit, complete
denervation was observed in the muscles innervated by
the medial trunk. (Table 1)
Based on their clinical features, all patients had severe
pain accompanied by sensory symptoms. The initial VAS
and LANSS scores were 7.53 ± 1.06 (range: 6–9) and 17.35
± 3.12 (range: 13–24). Except for 2 patients with only
sensory symptoms, all patients had drop foot. The initial
MRC Muscle Power Scale classifications were grade 0 in 2
(11.8%), grade 2 in 1 (5.9%), grade 3 in 7 (41.2%), grade 4
in 5 (29.4%), and grade 5 in 2 (11.8%) patients. The type
of injection that caused the PISN was an analgesic in 14
(82.4%), a vitamin in 2 (11.8%), and an antibiotic in 1
(5.9%) patient. (Table 1)
The median VAS scores at the first hour and one month
after the PSNB were 3 and 4. The pairwise comparison of
VAS scores measured after 1 h and before (p = 0.000), 1
month after and before (p = 0.008), after 1 h and after
1 month (p = 0.039) were found to be significant. The
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Table 1. Baseline characteristics of patients at the initial
assessment.
Variable

Patients N = 17

Age (years)*

54.95 ± 12.55 (27–75)

Sex
Maleᵟ

n =12 (70.6%)

Femaleᵟ

n = 5 (29.4%)

Duration of symptomsᵟ
≤3 months

n = 11 (64.7%)

>3 months

n = 6 (35.3%)

VAS baseline*

7.53 ± 1.06 (6–9)

LANSS baseline*

17.35 ± 3.12 (13–24)

EPSs findingsᵟ
Lateral truncus

n = 5 (29.4%)

Medial truncus

n = 3 (17.6%)

Both trunci

n = 9 (52.9%)

Muscle power scaleᵟ
Grade 0

n = 2 (11.8%)

Grade 1

n = 0 (0%)

Grade 2

n = 1 (5.9%)

Grade 3

n = 7 (41.2%)

Grade 4

n = 5 (29.4%)

Grade 5

n = 2 (11.8%)

Injection contentᵟ
Analgesic

n = 14 (82.4%)

Vitamin

n = 2 (11.8%)

Antibiotic

n = 1 (5.9%)

The values are presented * as mean +/- standard deviation (minmax) and ᵟ as n (%).
VAS: Visual Analog Scale; LANSS: Leeds Assessment
of Neuropathic Symptoms and Signs pain scale; EPSs:
Electrophysiologic studies.

median LANSS score at before and one month after the
PSNB was 16 and 6. LANSS differenced measured before
and 1 month after PSNB (p = 0.000) was found to be
significant (Table 2, Figure 2 and 3).
LANSS: Leeds Assessment of Neuropathic Symptoms
and Signs pain scale, PSNB: popliteal sciatic nerve block
The mean VAS scores before and one month after the
PSNB in the patients with lateral or medial truncus injury
were 6.75 ± 0.46 and 3.00 ± 0.75, while patients with both
types of truncus injury were 8.22 ± 0.97 and 5.22 ± 1.71.
The mean LANSS before and one month after the PSNB
in the patients with lateral or medial truncus injury were

14.88 ± 1.24 and 19.56 ± 2.55, while patients with both
types of truncus injury were 3.88 ± 2.53 and 11.44 ± 5.68.
(Table 3)
The mean VAS scores before and one month after
the PSNB in the patients with duration of symptoms ≤3
months were 7.64 ± 1.02 and 3.64 ± 1.12, while patients
with a duration of symptoms >3 months were 7.33 ±
1.21 and 5.17 ± 2.31. The mean LANSS before and one
month after the PSNB in the patients with a duration of
symptoms ≤3 months were 17.36 ± 2.90 and 6.91 ± 4.23,
while patients with a duration of symptoms >3 months
were 17.33 ± 3.77 and 9.67 ± 8.21. (Table 3)
The mean VAS scores before and one month after the
PSNB in the patients with MRC of 3,4,5 (maximum) were
8.20 ± 0.78 and 5.00 ± 1.764, while patients with MRC
score of 0,1,2 (minimum) were 6.57 ± 0.53 and 3.00 ±
0.816, respectively .The mean LANSS before and one
month after the PSNB in the patients with MRC of 3,4,5
(maximum) were 19.10 ± 2.80 and 10.80 ± 5.73 , while
patients with MRC of 0,1,2 (minimum) were 14.86 ± 1.34
and 3.71 ± 2.69. (Table 3)
The effects of EPSs findings (p=0.001) and loss of
muscle strength (p = 0.001) were found significance,
but the duration of symptoms (p=0.36) was not found
significant on the VAS scores that measured after PSNB.
And also the effects of EPSs findings (p = 0.001) and loss
of muscle strength (p=0.004) were found significance,
but the duration of symptoms (p = 0.55) was not found
significant on the VAS scores that measured after PSNB
(Table 4)
4. Discussion
Many morphological and metabolic changes occur after
trauma to the peripheral nerve. These changes take place
not only in the region of damage but also in the nerve
trunk, in segments proximal and distal to the location of
the injury, and in the neuromuscular junction or sensory
receptors where the nerve fiber ends [11]. The biggest
difference between peripheral nerve injuries and other
tissue injuries is demonstrated by Wallerian degeneration,
which proceeds towards the neuronal structures distal to
the lesion [12]. In patients with PISN, the pain initially
extends from the hip to the foot and then may migrate
from the knee to the foot or from the ankle to the foot, this
phenomenon is likely due to Wallerian degeneration.
Inflammatory reactions and mediators play
an important role in nerve repair, but prolonged
inflammation may negatively affect recovery and lead to
the development of neuropathic pain [13]. The ectopic
discharge of activity from the injured site up-regulates and
sensitizes the nociceptors and thereby contributes to the
development of central sensitization [14]. Corticosteroids
may be an effective therapy for neuropathic pain because
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Table 2. The change and comprasion of VAS score over time.
Median

Percentile
25

Percentile
75

Test Statistic

Standard
Error

p
value

VAS score
Before PSNB
1 Hour after PSNB

7
3

7
2

8
4

1 Month after PSNB

4

3

5

1 Hour after PSNB-Before PSNB

1.882

0.343

0.000*

1 Month after PSNB-Before PSNB

1.029

0.343

0.008*

1 Month hour PSNB-1 Month after PSNB

–0.853

0.343

0.039*

LANSS score
Before PSNB

16

15

19

1 Month after PSNB

6

5

11

1 Month after PSNB-Before PSNB

0.000**

*Pairwise comparison of VAS scores with Friedman test. *** Wilcoxon test.
Significance values have been adjusted by the Bonferroni correction for multiple tests.
VAS: Visual Analog Scale ; LANSS: Leeds Assessment of Neuropathic Symptoms and Signs pain scale; PSNB: popliteal sciatic nerve
block

VAS Scores

8
7
6
5
4
3
2
1
0

Baseline

1 h after PSNB
Seri 1

Seri 2

1 mouth after PSNB
Seri 3

Figure
Trends
in the
change
in VAS
scores in sciatic
patientsneuropathy,
with PISN who underwent
VAS: 2:
Visual
Analog
Scale;
PISN:
post-injection
PSNB. VAS: Visual Analog Scale; PISN: postinjection sciatic neuropathy, PSNB: popliteal
PSNB:
popliteal
sciatic
nerve
blocksciatic nerve block

they inhibit pro-inflammatory cytokines, prostaglandin
synthesis, neural firing, input to central neurons, and also
neurogenic extravasation and perineural edema formation
by reducing substance P at the site of the nerve injury
[15,16]. Perineural corticosteroid injections also produce
analgesia in a variety of pain-related disorders, including
neuromas [17] and nerve entrapments [18]. Nevertheless,
only a few trials have investigated perineural corticosteroid
injections for PISN.
Trans-sacral block with corticosteroids through the
unilateral S1-S2-S3 sacral foramina has been reported to
induce recovery from pain with PISN [19,20]. In these
case series, a corticosteroid nerve blockade was performed
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proximal to the damaged nerve, whereas, in our study, it
was performed distal to the damaged nerve. We selected
the location of the nerve block based on the results of
neurological examinations and EPSs. We performed PSNB
because pain localization did not cover the entire sciatic
nerve dermatome but was mostly located in the tibial or
peroneal nerve dermatome, which was confirmed with
EPSs. In a study that investigated transcutaneous electrical
nerve stimulation (TENS) for the treatment of PISN,
placing the electrodes in the painful area was reported to
be sufficient for maximum pain relief [21]. Similarly, in the
present study, we performed PSNB because patients with
PISN reported that their pain was localized below the knee.
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LANSS Scores

18
16
14
12
10
8
6
4
2
0

Baseline

1 month after PSNB
Seri 1

Seri 2

Seri 3

LANSS:
Leeds Assessment
of Neuropathic
Signs pain
Figure
3: Trends
in the change
in LANSSSymptoms
scores inand
patients
withscale,
PISN who underwent
PSNB: popliteal sciatic nerve block
PSNB.

Table 3. VAS and LANSS scores before and 1 month after PSNB according to EPS findings, duration of symptoms,
and loss of muscle strength.
VAS
Before

VAS
1 month after

LANSS
Before

LANSS
1 month after

EPS findings
Lateral or medial truncus

6.75 ± 0.46

3.00 ± 0.75

14.88 ± 1.24

3.88 ± 2.53

Both trunci

8.22 ± 0.97

5.22 ± 1.71

19.56 ± 2.55

11.44 ± 5.68

Duration of symptoms
≤3months

7.64 ± 1.02

3.64 ± 1.12

17.36 ± 2.90

6.91 ± 4.23

>3months

7.33 ± 1.21

5.17 ± 2.31

17.33 ± 3.77

9.67 ± 8.21

Loss of muscle strength
Maximum (MRC 3,4,5)

8.20 ± 0.78

5.00 ± 1.764

19.10 ± 2.80

10.80 ± 5.73

Minimum (MRC 0,1,2)

6.57 ± 0.53

3.00 ± 0.816

14.86 ± 1.34

3.71 ± 2.69

The values are presented as mean+/-SD (min-max).
VAS: Visual Analog Scale; LANSS: Leeds Assessment of Neuropathic Symptoms and Signs pain scale; EPSs:
electrophysiologic studies.

A previous study reported the outcomes of distal
decompression of the peroneal nerve at the fibular
tunnel following sciatic nerve injury secondary to total
hip arthroplasty [22]. After performing peroneal nerve
decompression at the fibular tunnel, 65% of the patients
recovered dorsiflexion strength. The authors explained
this finding as follows: Disruption of axoplasmic flow as
a result of the nerve injury may also enlarge the nerve,
further exacerbating potential compression at known sites
of entrapment. Decompression of the peroneal nerve at
the fibular tunnel may then also allow improvement when
performing nerve glide exercises and also lessen existing
tension, which may promote potential recovery.
The loss of motor and sensory function in the expected
dermatome indicates the success of the PSNB, which is

typically administered with 2% lidocaine. Complete pain
relief one hour after the popliteal block depends on the
amount of membrane stabilizing and the analgesic effects
of the local anesthetic. After this local anesthetic wears off,
the VAS and LANSS pain scores had increased one month
after PSNB compared to only one hour after the PSNB.
Even so, the VAS and LANSS pain scores one month later
had decreased compared to the scores recorded before
the PSNB due to the anti-inflammatory effect of the
corticosteroid. We think that stronger and longer-term
analgesia can be achieved with repetitive blocks or pulsed
radiofrequency [23].
EPSs findings can vary from mild to severe involvement
depending on the severity of the PISN [24]. In studies
involving large case groups, the lateral trunk is often more
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Table 4. The effect of EPS findings, duration of symptoms, and loss of muscle strength
on VAS and LANSS scores measured before and after PSNB.
Mean Square

F test

p value

VAS 1 Month after PSNB –Before PSNB
EPS findings

28.904

18.170

0.001*

Duration of symptoms

2.924

0.880

0.363*

Loss of muscle strength

27.108

15.848

0.001*

LANSS 1 Month after PSNB –Before PSNB
EPS findings

317.779

16.009

0.001*

Duration of symptoms

14,439

0.360

0.557*

Loss of muscle strength

264.222

11.282

0.004*

*Tests of between-subjects effects.
VAS: Visual Analog Scale; LANSS: Leeds Assessment of Neuropathic Symptoms and Signs pain scale; EPSs:
electrophysiologic studies.

severely affected because it is located more lateral to the
sciatic nerve, where protective epineural connective tissue
and blood vessels are more tense [25]. In our study, the
lateral trunk was isolated or affected along with the medial
trunk, which confirmed this hypothesis.
Proximal nerve injuries above the knee are difficult to
treat because before irreversible changes occur, sprouts
must travel the long distance to reinnervate distal muscles.
While recovery is expected with conservative treatment
in partial function losses, if there is a complete or severe
loss of function in one or both trunks of the sciatic
nerve, spontaneous recovery does not occur, and surgical
intervention is required [26]. In our study, patients with a
greater severity of nerve damage on EPSs findings (injury
to both trunci) and a loss of muscle strength (MRC 3,4,5)
experienced a lower success of PSNB in pain management.
5. Conclusion
Although further studies involving a greater number of
patients are necessary, our study indicated the effectiveness

of PSNB with methylprednisolone in the management of
PISN, especially in patients with pain that is below the
knee. The effect of the proximity of the injection to the site
of the nerve injury remains unknown, and further studies
are needed. The length of time that elapsed after the nerve
injury did not affect but EPSs findings and loss of muscle
strength indicated the severity of the nerve damage affect
the success of PSNB in pain management. PSNB can be
applied before surgery in PISN patients who have not
recovered with spontaneous or conservative treatment.
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